Larimar Therapeutics (LRMR) Earnings Analysis
Larimar Therapeutics (LRMR) next reports earnings on 2026-08-13, consensus EPS -0.39 USD. Last quarter (2026-05-14) it beat with EPS -0.31 USD vs -0.53 USD est (+41.5%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -1.91.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does LRMR next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.39 USD |
| Revenue estimate | n/a |
LRMR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | -0.31 USD | -0.53 USD | +41.5% | Beat |
| 2026-03-19 | -0.73 USD | -0.44 USD | -65.9% | Miss |
| 2025-08-14 | -0.41 USD | -0.47 USD | +12.8% | Beat |
| 2025-04-30 | -0.46 USD | -0.42 USD | -9.5% | Miss |
| 2025-03-24 | -0.45 USD | -0.29 USD | -55.2% | Miss |
| 2024-10-30 | -0.24 USD | -0.37 USD | +35.1% | Beat |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
LRMR valuation and analyst view
| Trailing P/E | -1.91 |
|---|---|
| Trailing EPS | -1.94881 USD |
| Price / book | 2.17 |
| Dividend yield | 0.00% |
| Market cap | 0.34B |
| Analyst consensus | Buy (8 buy / 0 hold / 0 sell) |
| Avg price target | 5 USD |
Related research pages
Frequently asked questions
When is Larimar Therapeutics (LRMR)'s next earnings date?
Larimar Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.39 USD.
Did LRMR beat earnings last quarter?
In its 2026-05-14 report, LRMR posted EPS of -0.31 USD versus a -0.53 USD estimate — a beat of 41.5%.
What is LRMR's earnings track record?
Over the last 6 reported quarters with consensus data, LRMR beat estimates 3 times (50%).
What is LRMR's current P/E ratio and EPS?
LRMR trades at a trailing P/E of -1.91 on trailing EPS of -1.9488093034011345 USD.
What do analysts rate LRMR?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 5 USD.